Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Rencent years have witnessed great progress of the treatment of acute myeloid leukemia.
However, most patients have poor outcomes following the currently first-line DA(daunorubicin,
cytarabine)/IA(Idarubicin, cytarabine) chemotherapy, espiecially for the older patients and
those not eligiable for receiving allo-HSCT. Azacitidine (AZA) was listed to methylation of
drugs in China in 2018, is currently the only one approved methylation drugs in the treatment
of AML(acute myeloid leukemia), in the NCCN guidelines. The homoharringtonie could induce
AML(acute myeloid leukemia) cell lines and primary myeloid leukemia cell apoptosis, and the
effect was dose dependent. While, HHT could also induce leukemia cells to differentiate into
normal state, eventually achieve the goal of treatment, and control the disease. The
investigators conducted a clinical study to evaluate the efficacy and safety of the AZA plus
HAG(homoharringtonie, cytarabine, G-CSF), HIA(homoharringtonie, Idarubicin,
cytarabine)/HDA(homoharringtonie, daunorubicin, cytarabine). This study is aimed to validate
the efficacy and safety advantages of the regimens that cotain homoharringtonie and
azacitidine, and to determine which regimen would receive more living benefits.